Delirium: full guideline appendices

This page was last updated: 07 May 2010

Stakeholder list ^{PDF 119 KB} 31 October 2018
Surveillance review proposal ^{PDF 1.01 MB} 31 August 2018
Comments form ^{MSWord 28 KB} 31 August 2018
Stakeholder list - review proposal ^{PDF 191 KB} 30 October 2014
Review proposal ^{PDF 471 KB} 30 October 2014
Surveillance review decision ^{PDF 699 KB} 28 January 2015
Evidence update ^{PDF 350 KB} 01 April 2012
2010/103 New NICE guideline set to encourage healthcare professionals to 'think delirium' and take steps to prevent it ^{PDF 166 KB} 06 December 2013
Remit ^{PDF 14 KB} 31 October 2007
List of stakeholders ^{PDF 23 KB} 12 July 2010
Final scope ^{PDF 111 KB} 03 July 2008
Stakeholder comments on draft scope ^{PDF 199 KB} 12 August 2008
Draft scope for consultation ^{PDF 119 KB} 16 April 2008
Draft scope comments proforma ^{MSWord 48 KB} 16 April 2008
List of stakeholders ^{PDF 23 KB} 12 July 2010
Equalities impact assessment (recommendations) ^{PDF 29 KB} 28 July 2010
GDG membership list ^{PDF 19 KB} 03 July 2008
Delirium GDG minutes: 16 July 2009 ^{PDF 35 KB} 20 October 2009
Delirium GDG minutes: 15 July 2009 ^{PDF 35 KB} 20 October 2009
Delirium GDG minutes: 22 April 2009 ^{PDF 34 KB} 20 October 2009
Delirium GDG minutes: 3-4 July 2008 ^{PDF 38 KB} 22 October 2008
Delirium GDG minutes: 13 November 2008 ^{PDF 19 KB} 17 March 2009
Delirium GDG minutes: 21-22 January 2009 ^{PDF 20 KB} 22 April 2009
Delirium GDG minutes: 4 March 2009 ^{PDF 87 KB} 30 July 2009
Draft full guideline for consultation ^{PDF 1.85 MB} 11 November 2009
Algorithm ^{PDF 45 KB} 11 November 2009
Appendices and contents page ^{PDF 615 KB} 11 November 2009
Appendix D adverse effects - included studies ^{PDF 233 KB} 11 November 2009
Appendix D consequences of - included studies ^{PDF 155 KB} 11 November 2009
Appendix D diagnostic test accuracy - included studies ^{PDF 182 KB} 11 November 2009
Appendix D epidemiology - included studies ^{PDF 214 KB} 11 November 2009
Appendix D non pharmacological risk factors - included studies ^{PDF 90 KB} 11 November 2009
Appendix D pharmacological risk factors - included studies ^{PDF 49 KB} 11 November 2009
Appendix E consequences of cohort studies - methodological quality ^{PDF 125 KB} 11 November 2009
Appendix E diagnostic accuracy tests - methodological quality ^{PDF 172 KB} 11 November 2009
Appendix E epidemiology - methodological quality ^{PDF 168 KB} 11 November 2009
Appendix E non-pharmacological risk factors cohort studies - methodological quality ^{PDF 44 KB} 11 November 2009
Appendix E pharmacological risk factors cohort studies - methodological quality ^{PDF 29 KB} 11 November 2009
Appendix E patient information - methodological quality ^{PDF 213 KB} 11 November 2009
Appendix F consequences of - multivariate risk factors ^{PDF 185 KB} 11 November 2009
Appendix F - non-pharmacological risk factors - multivariate risk factors ^{PDF 293 KB} 11 November 2009
Appendix F pharmacological risk factors - multivariate risk factors ^{PDF 63 KB} 11 November 2009
Appendix G diagnostic test accuracy - excluded studies ^{PDF 128 KB} 11 November 2009
Appendix G adverse effects review - excluded studies ^{PDF 121 KB} 11 November 2009
Appendix G consequences of - excluded studies ^{PDF 55 KB} 11 November 2009
Appendix G epidemiology review - excluded studies ^{PDF 146 KB} 11 November 2009
Appendix G non-pharmacological risk factors - excluded studies ^{PDF 71 KB} 11 November 2009
Appendix G information for patients review - excluded studies ^{PDF 118 KB} 11 November 2009
Appendix G pharmacological risk factors - excluded studies ^{PDF 55 KB} 11 November 2009
Appendix G references to excluded studies ^{PDF 151 KB} 11 November 2009
Appendix K evidence summary - prevention ^{PDF 34 KB} 11 November 2009
Appendix K evidence summary - treatment ^{PDF 39 KB} 11 November 2009
Draft NICE guideline for consultation ^{PDF 250 KB} 11 November 2009
Consultation table and with developers responses ^{PDF 1.02 MB} 07 May 2010
Pre-publication check - stakeholder comments/developer responses ^{PDF 49 KB} 28 July 2010
Full guideline ^{PDF 3.5 MB} 07 May 2010
Appendix A - Scope ^{PDF 64 KB} 07 May 2010
Appendix B - Declaration of Interests ^{PDF 49 KB} 07 May 2010
Appendix C - Search Strategies ^{PDF 174 KB} 07 May 2010
Appendix D - Adverse Effects - Included studies ^{PDF 121 KB} 07 May 2010
Appendix D - Consequences of - Included studies ^{PDF 155 KB} 07 May 2010
Appendix D - Diagnostic Test Accuracy - Included Studies ^{PDF 182 KB} 07 May 2010
Appendix D - Epidemiology - Included studies ^{PDF 91 KB} 07 May 2010
Appendix D - Non pharmacological Risk factor - Included studies ^{PDF 44 KB} 07 May 2010
Appendix D - Pharma Nonpharma Prevention Treatment - Included studies ^{PDF 170 KB} 07 May 2010
Appendix D - Pharmacological Risk factors - Included studies ^{PDF 49 KB} 07 May 2010
Appendix E - Consequences of ^{PDF 125 KB} 07 May 2010
Appendix E - Diagnostic Accuracy Tests Methodological Quality ^{PDF 172 KB} 07 May 2010
Appendix E - Epidemiology quality ^{PDF 71 KB} 07 May 2010
Appendix E - Non Pharmacological Risk Factors ^{PDF 44 KB} 07 May 2010
Appendix E - Patient info quality ^{PDF 80 KB} 07 May 2010
Appendix E - Pharma NonPharma Prevention Treatment ^{PDF 107 KB} 07 May 2010
Appendix E - Pharmacological Risk Factors review - Randomised controlled trials ^{PDF 23 KB} 07 May 2010
Appendix E - Pharmacological Risk Factors review - cohort studies ^{PDF 30 KB} 07 May 2010
Appendix G - References for Excluded Studies ^{PDF 93 KB} 07 May 2010
Appendix H - Recommendations for Future Research ^{PDF 75 KB} 07 May 2010
Appendix I - DSM-IV and Scales For Measuring ^{PDF 64 KB} 07 May 2010
Appendix J - Health Economics ^{PDF 155 KB} 07 May 2010
Appendix K - Forest Plots ^{PDF 462 KB} 07 May 2010
Consultation table and with developers responses ^{PDF 1.02 MB} 07 May 2010